1. Introduction {#sec1}
===============

The dependency of a tumour on a specific oncogene, for example the epidermal growth factor receptor type 1 (EGFR), renders it potentially sensitive to inhibitors that preferentially target the altered oncogene [@bib1]. The EGFR, a receptor-tyrosine kinase, can be transactivated by G protein-coupled receptors and controls cell growth and proliferation via a transduction signalling pathway [@bib2]. A mutation of this receptor can lead to over expression of the tyrosine kinase domain in the cell membrane [@bib3], [@bib4]. The result of this is unregulated cell growth and proliferation [@bib3], [@bib4]. Identifying the genotype of a cancer therefore enables a more targeted approach towards treatment. Tyrosine kinase inhibitors (TKIs), such as Erlotinib, are able to halt these tumour promoting properties in EGFR mutated non-small-cell lung cancers [@bib5], [@bib6]. They achieve an average tumour control of 11 months [@bib7]; however, resistance mechanisms such as the T790M mutation within exon 20 can develop with loss of tumour control [@bib6], [@bib8]. Osimertinib is a third generation EGFR TKI that exhibits activity towards the T790M mutation [@bib9]. This patient case study demonstrates the extended ongoing survival (over 4 years) achieved by sequentially targeting the EGFR1 gene mutations as they arose and highlights the importance of looking for such acquired resistance mutations.

2. Case report {#sec2}
==============

A 56-year-old retired midwife and non-smoker, diagnosed with metastatic non-small-cell lung cancer was referred to the Oncology Department, Plymouth Hospitals NHS Trust, in late 2012. Her performance status was 1 with a past medical history of hypothyroidism, hypercholesterolemia, prior breast reduction surgery and hysterectomy. A CT guided biopsy confirmed a left upper lobe adenocarcinoma, T4 N3 M1b, with EGFR gene mutation positive; this was a deletion mutation within exon 19 which was predicted to be a sensitising mutation to EGFR tyrosine kinase inhibitors.

The patient was commenced on Carboplatin and Pemetrexed chemotherapy (as EGFR analysis was not available until March 2013), however due to toxicity this was discontinued after 2 cycles. A first generation TKI, Erlotinib (Tarceva) 150mg once daily was commenced in March 2013. The patient responded and remained well, in remission until February 2015 ([Fig. 1](#fig1){ref-type="fig"}). Thereafter, symptoms including tiredness, headaches, back pain and diarrhoea began to increase. This prompted a repeat CT abdomen, thorax and pelvis scan which revealed disease progression in the form of an enlarging left pleural effusion with stable upper lobe mass. The patient then underwent 10 cycles of weekly carboplatin and paclitaxel chemotherapy which was tolerated well with minimal side effects. A further chest x-ray confirmed response prompting a switch to maintenance Pemetrexed chemotherapy in May 2015.

At a routine clinic appointment, new onset pain in the lumbar spine was noted. Spinal x-rays revealed degenerative changes. An urgent nuclear medicine bone scan was undertaken in November 2015. This revealed scattered osteoblastic metastases involving the right scapula, right ninth rib, L2 and L3 pedicle, right iliac crest and left ilium. A subsequent restaging CT scan of the thorax, abdomen, pelvis and brain revealed that the left upper lobe spiculated mass had increased in size in addition to multiple new pulmonary metastases, left supraclavicular lymphadenopathy and a bone metastasis within the L2 vertebral body. The CT brain scan in December 2015 identified multiple brain metastases; treatment was commenced with high dose Dexamethasone, Denosumab for bony metastases, Phenytoin for seizure prophylaxis and whole brain radiation therapy. She continued to deteriorate. An ultrasound guided repeat biopsy of the left supraclavicular fossa lesion was performed. Histopathology results showed an acquired T790M mutation within exon 20 using the Roche Cobas EGFR assay. This is a real time PCR amplification assay of the EGRF1 gene, which will detect mutations at a level \>5% in a background of wild-type DNA; it covers 85% of known mutations within the EGFR TK domain exons 18--21 [@bib10]. A third generation EGFR TKI, Osimertinib (Tagrisso), 80mg once daily was commenced in late February 2016 under the extended access programme. From this point forward, investigations show resolution of brain metastases and review is ongoing ([Fig. 2](#fig2){ref-type="fig"}).

3. Discussion {#sec3}
=============

The oncogenes directly associated with non-small-cell lung cancer mutations for which treatment is available are: EGFR - accounting for 10--15% of non-squamous non-small cell lung cancers in Western populations [@bib6], [@bib11], and anaplastic lymphoma kinase (ALK) which accounts for 3--5% [@bib12] of non-squamous non-small cell lung cancers. These driver genotypes determine the corresponding active treatment. First generation TKIs, such as Erlotinib, have been shown to provide substantially better response rates in comparison with standard chemotherapy regimes in patients with a sensitising EGFR mutation [@bib6], [@bib13]. EGFR dimerization stimulates its intrinsic intracellular protein-tyrosine kinase activity; by reversibly binding to EGFR the TKI preferentially inhibits the binding of the ATP to the tyrosine kinase domain thereby halting cell proliferation, leading to cell death [@bib3]. The second-generation EGFR-TKIs such as Afatinib irreversibly bind to the tyrosine kinase of EGFR. Afatinib has also been approved as first-line treatment of advanced NSCLC harbouring activating EGFR mutations [@bib14].

Acquired resistance to first generation TKI may arise through secondary mutation of the EGFR - such as T790M mutation within exon 20, by bypass tracks arising from MET amplification, P13K mutations or small cell transformation [@bib15], [@bib16]. The T790M mutation, as in this case, is found in up to 60% of EGFR TKI- treated tumours [@bib8], [@bib15], [@bib17] and is a point mutation at codon 790 substituting methionine for threonine in the EGFR gene [@bib15]. These T790M mutations arrive either innately, or upon treatment with a TKI as a resistance mutation [@bib15]. The T790M mutation has a higher affinity to binding ATP and therefore activates the transduction signalling pathway and promotes tumour growth ([Fig. 3](#fig3){ref-type="fig"}) [@bib8].

Third generation TKIs can inhibit EGFR resistance mutations [@bib8]. Osimertinib (Tagrisso) is a 3rd generation TKI which forms an irreversible covalent bond to EGFR, specifically targeting the T790M mutation [@bib9]. Licensed for use in the EU since February 2016 for patients with EGFR T790M mutation positive non-small-cell-lung cancers; it has been found in Phase II studies to have an objective response rate (ORR) in the region of 67% [@bib8]. Progression free survival has been recorded at 9.6 months [@bib8]. Treatment is generally well tolerated. Side effects include diarrhoea, skin and nail changes, stomatitis, or rarely QT interval prolongation, shortness of breath/pneumonitis and bone marrow suppression [@bib9]. Thus far diarrhoea is the only reported side effect in this case.

To conclude, our ability to identify the oncogenes responsible for non-small-cell lung cancers means that we are now able to offer specifically targeted treatments, as in the case of this lady with metastatic non-small-cell lung cancer. Studies to-date suggest that TKI therapies offer significant opportunity. Third generation TKIs have helped to address issues of acquired resistance in T790M mutations. Further studies are ongoing to establish the comparative benefits of Osimertinib versus chemotherapy for patients with EGFR T790M mutation positivity. This patient\'s extended survival and maintained quality of life are an example of the benefits that are consequent to the use of these modern, genotype-targeted personalised therapies for metastatic non-small-cell lung cancer. Gaining the full benefits of anti EGFR1 strategies requires repeated testing of this oncogene. This is most commonly undertaken by repeat biopsy as in this case, although circulating tumour DNA (ctDNA) technology may help us look for specific mutations such as the T790m mutation [@bib18].
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